We are almost out of money (again) and a run at a profitable CDMO is a last gasp (IMO) for the current BOD’s to resurrect this company.
Wow....looks like John Stafford spent a large amount of effort for nothing, according to your opinion
The FDA, according to reports....would take action IF there were mucho adverse events occurring after patients were in a particular trial and they would no longer think twice about halting such a trial
On the Bavi flipside, a subgroup of patients that liver longer than all others, breaking historical norm records of MOS, would also be something to act upon, especially if they all had immune systems PRIMED via Bavi
The FDA could repair partially this broken system which is broken for the advantage of some